To all: Stressgen's 3rd new patent this month is European and covers both "method of use" and "composition of matter":
Stressgen's new European patent for heat shock protein fusions maximizes international marketing opportunities
SAN DIEGO, CA, Jan. 23 /CNW/ - Stressgen Biotechnologies Corporation (TSE: SSB) announced that the European Patent Office has granted Patent Number 700445 B1 covering compositions and methods for using fusion proteins comprised of heat shock proteins fused to antigens. Stressgen has exclusively licensed this technology from the Whitehead Institute for Biomedical Research.
Using this patented heat shock protein 'fusion' technology, Stressgen is developing its lead product, HspE7, for the treatment of diseases caused by human papillomavirus (HPV), one of the most common causes of sexually transmitted disease in the world. The Company is researching other fusion candidates to treat hepatitis B virus, herpes simplex virus and HIV.
"This is the third important patent received this month on our heat shock protein 'fusion' technology," said Daniel L. Korpolinski, President and Chief Executive Officer of Stressgen. "This additional patent strengthens our solid intellectual property portfolio and, combined with recently granted U.S. patents, advances the implementation of our global branding strategy for our proprietary family of immunotherapeutic drugs."
About Stressgen Biotechnologies
Stressgen is a public biopharmaceutical company focused on the development and commercialization of innovative stress protein-based 'fusion' immunotherapeutics. The Company is developing a broad range of products for the treatment of viral infections and related cancers. Stressgen is also an internationally recognized commercial supplier of research products used by scientists worldwide for the study of cellular stress, apoptosis, oxidative stress and neurobiology.
HspE7 is a novel immunotherapeutic for the treatment of diseases caused by the human papillomavirus ("HPV"), one of the most common sexually transmitted diseases, estimated to infect approximately 50 percent of the sexually active population. There are 5.5 million new cases of genital HPV infection diagnosed per year in the U.S. alone, of which over 1 million represent cases of genital warts. In addition to warts, genital HPV infection can cause cervical cancer and a variety of precancerous conditions, including anal and cervical dysplasia.
newswire.ca
Heat. |
